EHA 2021 | Is MRD-based therapy hope, hype, or reality?
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, shares his views on the benefits of incorporating measurable residual disease (MRD) as a prognostic tool into the treatment of multiple myeloma, and outlines MRD’s potential role in decision-making in the future. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Transcript (edited for clarity)
I think that MRD is everything in myeloma, hype, hope and reality. Due to intensive research in the last decade, I think that it is clearly established as one of the most, if not the most, relevant prognostic factor in myeloma. It is more and more being considered as a treatment endpoint, particularly in newly diagnosed patients. And in my opinion, we are now learning through innovative clinical trials, how to potentially use MRD to guide treatment decisions in clinical practice...
I think that MRD is everything in myeloma, hype, hope and reality. Due to intensive research in the last decade, I think that it is clearly established as one of the most, if not the most, relevant prognostic factor in myeloma. It is more and more being considered as a treatment endpoint, particularly in newly diagnosed patients. And in my opinion, we are now learning through innovative clinical trials, how to potentially use MRD to guide treatment decisions in clinical practice.
Read more...
